Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nintedanib for progressive fibrosing interstitial lung disease	Nintedanib (Vargatef; Ofev; nintedanib esilate)	Progressive fibrosing interstitial lung disease (PF-ILD)	Respiratory System	2019	View \| Download
Nerinetide for acute ischaemic stroke	Nerinetide (NA-1)	Ischaemic stroke	Cardiovascular System	2019	View \| Download
MTX-110 for newly-diagnosed diffuse intrinsic pontine glioma	Panobinostat (MTX-110; Farydak; LBH589; LBH-589; panobinostat lactate anhydrous)	Glioma	Neurological Cancer	2019	View \| Download
Migalastat for Fabry disease in children aged 12 to 15 years	Migalastat hydrochloride (Galafold; AT1001)	Fabry disease	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2019	View \| Download
Mechlorethamine gel for mycosis fungoides in cutaneous T-cell lymphoma	Mechlorethamine (Ledaga; Valchlor)	Cutaneous T-cell lymphoma (CTCL)	Haematological Cancer and Lymphomas	2019	View \| Download
LY-900014 (ultra-rapid lispro) for adults with type 1 diabetes mellitus	Insulin lispro (LY-900014)	Type 1 diabetes	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download
Lumasiran for primary hyperoxaluria type I	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
Lumasiran for primary hyperoxaluria type 1 in paediatric patients aged up to 5 years	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
Lumacafor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 to 23 months	Orkambi (fixed dose combination: Lumacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Liraglutide for weight management in obese adolescents aged 12-17 years old	Liraglutide (Victoza; NN-2211; NN-2211 Pen Injector)	Weight management	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download